Tag: BTK

R3 Vascular

R3 Vascular reports the initiation of its first-in-human clinical study

R3 Vascular has reported the successful initiation of its first-in-human clinical study evaluating the technical and clinical performance of the R3 Vascular Magnitude bioresorbable...
MedAlliance SELUTION SLR

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrolment

MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of...

FDA advisory panel recommends against premarket approval of Lutonix 014 DCB...

A US Food and Drug Administration (FDA) advisory panel has recommended against premarket approval of BD’s Lutonix 014 drug-coated balloon (DCB) for use in...

Study shows those with in-tack restenosis have shorter lesions than those...

Raghu Kolluri (Columbus, USA) talks to Vascular News about a recent comparative study looking at differences between in-tack and in-stent restenosis. The study examined...

LINC 2021: Novel approaches and new data for BTK interventions revealed

In a late-breaking trial session at LINC 2021 (The Leipzig Interventional Course, 25–29 January, online), key updates on below-the-knee (BTK) interventions were in the...

Combination of scaffold and drug in BTK intervention “without question” the...

 Sahil Parikh (New York, USA) talks to Brian DeRubertis (Los Angeles, USA) at VEITHsymposium 2019 (19–23 November, New York, USA) about the future of below-the-knee...

OUTBACK™ Elite Re-entry catheter highly effective at saving limbs in extreme...

 Lorenzo Patrone (London, UK) shares with BLearning at CIRSE 2019 (7–11 September, Barcelona, Spain) the benefits of using the OUTBACK™ Elite Re-entry Catheter (Cordis,...

Lutonix BTK IDE: First Level 1 evidence of positive safety and...

 Patrick Geraghty (St Louis, USA) presented new datapoints from the six-month outcomes of the Lutonix BTK IDE trial at the 2018 VEITHsymposium (13–17 November,...

SAVAL trial of new below-the-knee drug-eluting stent begins

The first patient has been enrolled in the SAVAL pivotal trial to evaluate clinical outcomes of the SAVAL below-the-knee (BTK) drug-eluting stent system (Boston...

First-ever CE mark of a bioresorbable scaffold for below-the-knee PAD

Reva Medical, a company developing bioresorbable polymer technologies for vascular applications, has announced that its Motiv bioresorbable scaffold is the first drug-eluting bioresorbable scaffold...